RPEXE.RPEXT: Reduced Piecewise Exponential Estimate/Test Software

Description References


This reduced piecewise exponential survival software implements the likelihood ratio test and backward elimination procedure in Han, Schell, and Kim (2012, 2014), and Han et al. (2016). Inputs to the program can be either times when events/censoring occur or the vectors of total time on test and the number of events. Outputs of the programs are times and the corresponding p-values in the backward elimination. Details about the model and implementation are given in Han et al. 2014. This program can run in R version 3.2.2 and above.


[1] Han, G., Schell, M. J., and Kim, J. (2012) “Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test," Statistics in Biopharmaceutical Research, 4(4), 348-356.

[2] Han, G., Schell, M. J., and Kim, J. (2014) “Improved Survival Modeling in Cancer Research Using a Reduced Piecewise Exponential Approach," Statistics in Medicine, 33(1), 59-73.

[3] Han, G., Schell, M., Zhang, H., Zelterman, D., Pusztai, L., Adelson, K., and Hatzis, C. (2016) “Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints," Biometrics, DOI: 10.1111/biom.12590; PMID: 27669414.

[4] Adelson, K. B., Ramaswamy, B., Sparano, J. A., Christos, P. J., Wright, J. J., Raptis, G., Han, G., Villalona-Calero, M., Ma, C., Hershman, D., Baar, J., Klein, P., Cigler, T., Budd, T., Novik, Y., Tan, A.R., Tannenbaum, S., Goel, A., Levine, E., Shapiro, C. L., Andreopoulou, E., Naughton, M., Kalinsky, K., Waxman, S., Germain, D. (2016) “Randomized Phase II Trial of Fulvestrant Alone or in Combination with Bortezomib in Hormone Receptor-Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitors: A New York Cancer Consortium Trial," Nature Partner Journals Breast Cancer, Volume 2, Article ID 16037, DOI: 10.1038/npjbcancer.2016.37.

[5] Simon GR, Extermann M, Chiappori A, Williams C, Begum M, Haura RKE, Ismail-Khan R, Schell M, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced stage non-small cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 2008; 112:2021–2029.

[6] Hatzis, C., Pusztai, L., Valero, V., Booser, D. J., Esserman, L., Lluch, A., et al. (2011). A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. The Journal of the American Medical Association 305, 1873–1881.

RPEXE.RPEXT documentation built on July 1, 2020, 6:02 p.m.